SLP•benzinga•
Simulations Plus Slashes Guidance Amid Biotech Spending Cuts, Analyst Expresses Doubt
Summary
Simulations Plus stock fell after it issued a weaker 2025 outlook and forecast Q3 revenue below expectations, citing biotech market pressures.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 12, 2025 by benzinga